Developer docs
API playgroundTry for free, no card

Search company profiles

D. E. Shaw Research

Full company profile

uuid0007oeh

Namestring
D. E. Shaw Research
Legal namestring
D. E. Shaw Research, LLC
Company typeenum
Private
Founded yearint
2002
Descriptiontext

D. E. Shaw Research is a privately held scientific research and drug discovery company headquartered in New York, founded in 2002 as part of the broader D. E. Shaw group. The company develops special-purpose supercomputers and computational methods to understand pharmaceutically significant biomolecules at atomic resolution and to design precisely targeted therapeutics. Its core technology platform centers on the Anton family of supercomputers (three generations developed in-house, with Anton 3 the latest), purpose-built ASIC-class hardware that executes molecular dynamics simulations roughly 100 times faster than general-purpose supercomputers, enabling observation of millisecond-scale biological phenomena previously inaccessible to simulation. The platform is complemented by the Desmond MD simulation software package, made available at no cost to academic institutions, and by machine learning methods applied both independently and as integrated elements of Anton-enabled workflows, including neural networks trained on Anton-generated trajectory data.

The business operates two parallel drug discovery programs. The independent program has produced two clinical-stage candidates (DES-9384 targeting TRPA1 for neuropathic pain and chronic cough, and DES-7987 targeting KCa3.1 for asthma and lung fibrosis). The collaborative program, anchored by a 2016 multi-target alliance with Relay Therapeutics (a D. E. Shaw Research co-founded company), has generated four additional clinical-stage candidates, including RLY-4008 (an FGFR2 inhibitor licensed to Elevar Therapeutics in 2024 for cholangiocarcinoma and other solid tumors) and RLY-2608 (a mutant-selective allosteric PI3Kα inhibitor for breast cancer and vascular malformations). Revenue mechanics center on licensing, royalty, and collaborative development arrangements with pharmaceutical and biotech partners, supplemented by free academic access programs that build the research ecosystem and talent pipeline.

The company sells primarily through direct enterprise engagement with pharmaceutical and biotechnology companies seeking computational drug discovery partnerships, with no traditional consumer channel. Headcount sits in the 101-250 range, and the firm is founder-controlled under David E. Shaw as Chief Scientist, operating without external venture capital, private equity, or institutional investment. Compensation disclosure (with senior AI/ML research roles ranging $350K-$1M) suggests a top-quartile technical talent base, and the firm's research output is anchored by publications in Science, Nature, and PNAS, two Gordon Bell Prizes (2009, 2014), and a 2010 Science "Breakthrough of the Year" recognition.

Short descriptiontext

D. E. Shaw Research is a private New York-based computational biochemistry company that builds special-purpose Anton supercomputers for molecular dynamics simulations and applies them, alongside machine learning, to drug discovery. It runs an independent clinical-stage pipeline (DES-9384, DES-7987) and collaborates with Relay Therapeutics on additional clinical candidates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular dynamics simulation, computational drug discovery, special-purpose supercomputers, biomolecular simulation software, computational biochemistry research
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Computational Drug Discovery
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Discovery Collaborations
TypeLicensing Royalties
Description

The company conducts drug discovery programs both independently and in collaboration with other biopharmaceutical companies and research laboratories. Revenue is generated through licensing agreements and collaborative development arrangements, such as the multi-target collaboration with Relay Therapeutics.

deshawresearch.com
2Independent Drug Development
TypeLicensing Royalties
Description

Development of proprietary drug candidates through clinical trials, with three independently designed drugs (DES-9384, DES-7987) having reached clinical stage. Potential future revenue through drug approval and commercialization.

deshawresearch.com
3Technology Access (Anton)
TypeLicensing Royalties
Description

Anton supercomputer access provided without cost for non-commercial research use by U.S. universities and not-for-profit institutions. Desmond software available at no cost for academic institutions. This supports research ecosystem and potential future collaborations.

deshawresearch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Infrastructure, Operations
Pricing details7 tiers
1Summer Internship Program
ModelOtherBilling cadenceMonthly
Notes

Expected monthly salary: $11,700-$20,600. Generous housing allowance provided.

deshawresearch.com
2Data Associate Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $170,000-$210,000 plus sign-on and year-end bonuses

deshawresearch.com
3LLM Researcher and Engineer Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $450,000-$1,000,000 plus bonuses and benefits

deshawresearch.com
4Machine Learning Researcher and Engineer Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $350,000-$900,000 plus bonuses and benefits

deshawresearch.com
5Scientific Software Developer Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $250,000-$600,000 plus bonuses and benefits

deshawresearch.com
6Information Security Engineer, Agentic AI Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $250,000-$800,000 plus bonuses and benefits

deshawresearch.com
7Systems Engineer Position
ModelOtherBilling cadenceAnnual
Notes

Expected annual base salary: $250,000-$800,000 plus bonuses and benefits

deshawresearch.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

D. E. Shaw Research develops special-purpose Anton supercomputers and novel computational methods to perform ultra-high-resolution molecular dynamics simulations of biological molecules. It applies these technologies, combined with machine learning, to elucidate molecular mechanisms of disease, identify therapeutic targets, and design precisely targeted drug candidates, including seven clinical-stage drugs (three developed independently and four in collaboration with Relay Therapeutics).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100x faster molecular dynamics simulations compared to general-purpose supercomputers
+3 more records
Product overview1 text field

D. E. Shaw Research offers a technology platform centered on Anton, a special-purpose supercomputer for ultra-high-resolution molecular dynamics simulations, supplemented by the Desmond MD simulation software package available to academic institutions. Their drug discovery services use Anton-based simulations, machine learning methods, and advanced computational technologies to elucidate molecular mechanisms, identify pharmaceutical intervention strategies, and design novel therapeutics. The company has brought seven clinical-stage drugs into trials, including three independently developed candidates (DES-9384 targeting TRPA1, DES-7987 targeting KCa3.1) and four developed in collaboration with Relay Therapeutics.

Product and service5 records
1Anton Supercomputer System
CategoryCore Technology / Hardware Platform
Description

Special-purpose supercomputer for molecular dynamics simulation, executing biological MD simulations approximately 100 times faster than general-purpose supercomputers; offered without cost for non-commercial research use to U.S. universities and not-for-profit institutions.

2Desmond MD Simulation Software
CategorySoftware Product
Description

Molecular dynamics simulation software package that runs on commodity GPUs, available at no cost for academic and not-for-profit research use.

3Anton-based Drug Discovery Programs
CategoryDrug Discovery Services
Description

Computational drug design service combining Anton-based MD simulations with experimental validation, encompassing elucidation of molecular mechanisms, identification of intervention strategies, and creation of precisely targeted therapeutics; delivered through licensing and collaborative development arrangements.

4DES-9384 Clinical-Stage Drug Candidate
CategoryClinical-Stage Drug Candidate
Description

Clinical-stage drug candidate independently developed by D. E. Shaw Research that inhibits TRPA1, a protein involved in diabetic peripheral neuropathic pain, chronic lower back pain, and chronic cough.

5DES-7987 Clinical-Stage Drug Candidate
CategoryClinical-Stage Drug Candidate
Description

Clinical-stage drug candidate independently developed by D. E. Shaw Research that inhibits KCa3.1, a protein implicated in asthma, ischemic stroke, and lung fibrosis.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Elevar Therapeutics received a license from Relay Therapeutics for RLY-4008, a FGFR2 inhibitor originally discovered through the D. E. Shaw Research - Relay Therapeutics collaboration. RLY-4008 is being developed as a potential therapy for cholangiocarcinoma and other solid tumors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

D. E. Shaw Research co-founded Relay Therapeutics and maintains a multi-target collaboration and licensing agreement. Four clinical-stage drugs (including RLY-4008 and RLY-2608) were discovered under this collaboration. RLY-4008 targets FGFR2 receptor tyrosine kinase and was licensed by Relay to Elevar Therapeutics in 2024 as potential therapy for cholangiocarcinoma and other solid tumors. RLY-2608 is a first-in-class mutant-selective allosteric PI3Kalpha inhibitor being studied for breast cancer, solid tumors, and vascular malformations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public computational chemistry and materials science platform combining physics-based simulation with ML for drug and materials discovery; directly competes with D. E. Shaw Research for pharma computational discovery partnerships.

2Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed drug discovery company built on AlphaFold and DeepMind AI foundations; pursues AI-first drug design at scale with significantly larger capital, making it a peer for AI-enabled molecular design partnerships.

TypeEmerging player
Description

Provides molecular modeling, cheminformatics, and MD simulation software for drug discovery; overlaps with the Desmond software product and cheminformatics modeling category.

TypeEmerging player
Description

AI + physics-based drug discovery company combining quantum physics, cloud HPC, and ML to predict crystal structures and molecular properties; comparable platform play with significant China-based operations.

TypeDirect peer
Description

Clinical-stage precision medicine company co-founded by D. E. Shaw Research using its motion-based drug design platform; closest comparable in motion-based computational drug discovery and a strategic commercialization vehicle for DESRES-discovered assets.

TypeDirect peer
Description

Machine-learning driven drug discovery company combining induced pluripotent stem cell biology with ML models; competes for ML-enabled drug discovery talent and pharma collaboration deals.

TypeDirect peer
Description

AI-driven biotech combining high-throughput wet-lab experimentation with ML to discover and develop therapeutics; competes for AI/ML-enabled drug discovery partnerships and talent.

TypeDirect peer
Description

AI-driven precision medicine company with clinical-stage assets designed end-to-end by its AI platform; peer in AI-first drug discovery targeting pharmaceutical partners.

TypeDirect peer
Description

AI-driven small molecule discovery company using structure-based deep learning models for hit identification; directly comparable as an AI/ML-first drug discovery platform targeting similar pharma partners.

TypeBroad incumbent
Description

Operates the AlphaFold protein structure prediction platform widely used in computational drug discovery; sets the bar for ML-based structural biology that competing platforms, including DESRES, must integrate with or differentiate from.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

D. E. Shaw Research

Computational Drug Discoverydeshawresearch.com

D. E. Shaw Research is a private New York-based computational biochemistry company that builds special-purpose Anton supercomputers for molecular dynamics simulations and applies them, alongside machine learning, to drug discovery. It runs an independent clinical-stage pipeline (DES-9384, DES-7987) and collaborates with Relay Therapeutics on additional clinical candidates.

What D. E. Shaw Research does

D. E. Shaw Research is a privately held scientific research and drug discovery company headquartered in New York, founded in 2002 as part of the broader D. E. Shaw group. The company develops special-purpose supercomputers and computational methods to understand pharmaceutically significant biomolecules at atomic resolution and to design precisely targeted therapeutics. Its core technology platform centers on the Anton family of supercomputers (three generations developed in-house, with Anton 3 the latest), purpose-built ASIC-class hardware that executes molecular dynamics simulations roughly 100 times faster than general-purpose supercomputers, enabling observation of millisecond-scale biological phenomena previously inaccessible to simulation. The platform is complemented by the Desmond MD simulation software package, made available at no cost to academic institutions, and by machine learning methods applied both independently and as integrated elements of Anton-enabled workflows, including neural networks trained on Anton-generated trajectory data.

The business operates two parallel drug discovery programs. The independent program has produced two clinical-stage candidates (DES-9384 targeting TRPA1 for neuropathic pain and chronic cough, and DES-7987 targeting KCa3.1 for asthma and lung fibrosis). The collaborative program, anchored by a 2016 multi-target alliance with Relay Therapeutics (a D. E. Shaw Research co-founded company), has generated four additional clinical-stage candidates, including RLY-4008 (an FGFR2 inhibitor licensed to Elevar Therapeutics in 2024 for cholangiocarcinoma and other solid tumors) and RLY-2608 (a mutant-selective allosteric PI3Kα inhibitor for breast cancer and vascular malformations). Revenue mechanics center on licensing, royalty, and collaborative development arrangements with pharmaceutical and biotech partners, supplemented by free academic access programs that build the research ecosystem and talent pipeline.

The company sells primarily through direct enterprise engagement with pharmaceutical and biotechnology companies seeking computational drug discovery partnerships, with no traditional consumer channel. Headcount sits in the 101-250 range, and the firm is founder-controlled under David E. Shaw as Chief Scientist, operating without external venture capital, private equity, or institutional investment. Compensation disclosure (with senior AI/ML research roles ranging $350K-$1M) suggests a top-quartile technical talent base, and the firm's research output is anchored by publications in Science, Nature, and PNAS, two Gordon Bell Prizes (2009, 2014), and a 2010 Science "Breakthrough of the Year" recognition.

D. E. Shaw Research firmographics

Firmographics
Name
D. E. Shaw Research
Legal name
D. E. Shaw Research, LLC
Website
https://deshawresearch.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
D. E. Shaw Research is a private New York-based computational biochemistry company that builds special-purpose Anton supercomputers for molecular dynamics simulations and applies them, alongside machine learning, to drug discovery. It runs an independent clinical-stage pipeline (DES-9384, DES-7987) and collaborates with Relay Therapeutics on additional clinical candidates.
Ownership category
akta.pro rank

D. E. Shaw Research industry classification

Industry
Product category
Computational Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Molecular dynamics simulation
  • Computational drug discovery
  • Special-purpose supercomputers
  • Biomolecular simulation software
  • Computational biochemistry research

Where D. E. Shaw Research is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

D. E. Shaw Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

  1. Drug Discovery Collaborations: The company conducts drug discovery programs both independently and in collaboration with other biopharmaceutical companies and research laboratories. Revenue is generated through licensing agreements and collaborative development arrangements, such as the multi-target collaboration with Relay Therapeutics.
  2. Independent Drug Development: Development of proprietary drug candidates through clinical trials, with three independently designed drugs (DES-9384, DES-7987) having reached clinical stage. Potential future revenue through drug approval and commercialization.
  3. Technology Access (Anton): Anton supercomputer access provided without cost for non-commercial research use by U.S. universities and not-for-profit institutions. Desmond software available at no cost for academic institutions. This supports research ecosystem and potential future collaborations.

Pricing tiers

ModelBillingPrice
OtherMonthlySummer Internship Program
OtherAnnualData Associate Position
OtherAnnualLLM Researcher and Engineer Position
OtherAnnualMachine Learning Researcher and Engineer Position
OtherAnnualScientific Software Developer Position
OtherAnnualInformation Security Engineer, Agentic AI Position
OtherAnnualSystems Engineer Position

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

D. E. Shaw Research product offering

Product offering

Core offering

D. E. Shaw Research develops special-purpose Anton supercomputers and novel computational methods to perform ultra-high-resolution molecular dynamics simulations of biological molecules. It applies these technologies, combined with machine learning, to elucidate molecular mechanisms of disease, identify therapeutic targets, and design precisely targeted drug candidates, including seven clinical-stage drugs (three developed independently and four in collaboration with Relay Therapeutics).

Product overview

D. E. Shaw Research offers a technology platform centered on Anton, a special-purpose supercomputer for ultra-high-resolution molecular dynamics simulations, supplemented by the Desmond MD simulation software package available to academic institutions. Their drug discovery services use Anton-based simulations, machine learning methods, and advanced computational technologies to elucidate molecular mechanisms, identify pharmaceutical intervention strategies, and design novel therapeutics. The company has brought seven clinical-stage drugs into trials, including three independently developed candidates (DES-9384 targeting TRPA1, DES-7987 targeting KCa3.1) and four developed in collaboration with Relay Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anton Supercomputer System Special-purpose supercomputer for molecular dynamics simulation, executing biological MD simulations approximately 100 times faster than general-purpose supercomputers; offered without cost for non-commercial research use to U.S. universities and not-for-profit institutions.
  • Desmond MD Simulation Software Molecular dynamics simulation software package that runs on commodity GPUs, available at no cost for academic and not-for-profit research use.
  • Anton-based Drug Discovery Programs Computational drug design service combining Anton-based MD simulations with experimental validation, encompassing elucidation of molecular mechanisms, identification of intervention strategies, and creation of precisely targeted therapeutics; delivered through licensing and collaborative development arrangements.
  • DES-9384 Clinical-Stage Drug Candidate Clinical-stage drug candidate independently developed by D. E. Shaw Research that inhibits TRPA1, a protein involved in diabetic peripheral neuropathic pain, chronic lower back pain, and chronic cough.
  • DES-7987 Clinical-Stage Drug Candidate Clinical-stage drug candidate independently developed by D. E. Shaw Research that inhibits KCa3.1, a protein implicated in asthma, ischemic stroke, and lung fibrosis.

Quantifiable outcome

  • 100x faster molecular dynamics simulations compared to general-purpose supercomputers
  • +3 more outcomes

Companies that use D. E. Shaw Research

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

D. E. Shaw Research technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

D. E. Shaw Research partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Elevar TherapeuticsminorStrategic or Co-development Partner · 1 January 2024Elevar Therapeutics received a license from Relay Therapeutics for RLY-4008, a FGFR2 inhibitor originally discovered through the D. E. Shaw Research - Relay Therapeutics collaboration. RLY-4008 is being developed as a potential therapy for cholangiocarcinoma and other solid tumors.
  • Relay TherapeuticscoreStrategic or Co-development Partner · 1 January 2016D. E. Shaw Research co-founded Relay Therapeutics and maintains a multi-target collaboration and licensing agreement. Four clinical-stage drugs (including RLY-4008 and RLY-2608) were discovered under this collaboration. RLY-4008 targets FGFR2 receptor tyrosine kinase and was licensed by Relay to Elevar Therapeutics in 2024 as potential therapy for cholangiocarcinoma and other solid tumors. RLY-2608 is a first-in-class mutant-selective allosteric PI3Kalpha inhibitor being studied for breast cancer, solid tumors, and vascular malformations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

D. E. Shaw Research competitors and assessment

Company assessment

Direct peers

  • Schrödinger, Inc. Public computational chemistry and materials science platform combining physics-based simulation with ML for drug and materials discovery; directly competes with D. E. Shaw Research for pharma computational discovery partnerships.
  • Isomorphic Labs: Alphabet-backed drug discovery company built on AlphaFold and DeepMind AI foundations; pursues AI-first drug design at scale with significantly larger capital, making it a peer for AI-enabled molecular design partnerships.
  • Relay Therapeutics: Clinical-stage precision medicine company co-founded by D. E. Shaw Research using its motion-based drug design platform; closest comparable in motion-based computational drug discovery and a strategic commercialization vehicle for DESRES-discovered assets.
  • Insitro: Machine-learning driven drug discovery company combining induced pluripotent stem cell biology with ML models; competes for ML-enabled drug discovery talent and pharma collaboration deals.
  • Recursion Pharmaceuticals: AI-driven biotech combining high-throughput wet-lab experimentation with ML to discover and develop therapeutics; competes for AI/ML-enabled drug discovery partnerships and talent.
  • Exscientia: AI-driven precision medicine company with clinical-stage assets designed end-to-end by its AI platform; peer in AI-first drug discovery targeting pharmaceutical partners.
  • Atomwise: AI-driven small molecule discovery company using structure-based deep learning models for hit identification; directly comparable as an AI/ML-first drug discovery platform targeting similar pharma partners.

Emerging players

  • OpenEye Scientific (Cadence Molecular Sciences): Provides molecular modeling, cheminformatics, and MD simulation software for drug discovery; overlaps with the Desmond software product and cheminformatics modeling category.
  • XtalPi: AI + physics-based drug discovery company combining quantum physics, cloud HPC, and ML to predict crystal structures and molecular properties; comparable platform play with significant China-based operations.

Broad incumbents

  • Google DeepMind (AlphaFold team): Operates the AlphaFold protein structure prediction platform widely used in computational drug discovery; sets the bar for ML-based structural biology that competing platforms, including DESRES, must integrate with or differentiate from.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

D. E. Shaw Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

D. E. Shaw Research leadership team

Management profile

Number of profiles

Profiles1 record

D. E. Shaw Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

D. E. Shaw Research M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D. E. Shaw Research

What does D. E. Shaw Research do?

D. E. Shaw Research develops special-purpose Anton supercomputers and novel computational methods to perform ultra-high-resolution molecular dynamics simulations of biological molecules. It applies these technologies, combined with machine learning, to elucidate molecular mechanisms of disease, identify therapeutic targets, and design precisely targeted drug candidates, including seven clinical-stage drugs (three developed independently and four in collaboration with Relay Therapeutics).

Is D. E. Shaw Research a public or private company?

D. E. Shaw Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was D. E. Shaw Research founded?

D. E. Shaw Research was founded in 2002. It employs 101 to 250 people.

Where is D. E. Shaw Research based?

D. E. Shaw Research is headquartered in New York, United States, in the North America region.

How does D. E. Shaw Research make money?

Three revenue lines are on record. Drug Discovery Collaborations are the primary driver. The others are independent Drug Development and technology Access (Anton).

Who are D. E. Shaw Research's main competitors?

Direct peers on record are Schrödinger, Inc., Isomorphic Labs, Relay Therapeutics, Insitro, Recursion Pharmaceuticals, Exscientia and Atomwise. Emerging players are OpenEye Scientific (Cadence Molecular Sciences) and XtalPi. Google DeepMind (AlphaFold team) is listed as a broad incumbent.

Does D. E. Shaw Research have an API?

No public API is recorded for D. E. Shaw Research.

What industry is D. E. Shaw Research in?

D. E. Shaw Research's product category is Computational Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals